Of the 251 patients with tumor assessments available to date, more than 95% showed some degree of therapeutic benefit. A complete response was documented in 17.5% of patients, a partial response in 39.8%, and 39% had stable disease. Fewer than 3% have experienced disease progression during this early follow-up period.
The ERIVANCE BCC and STEVIE studies are funded by Genentech. Dr. Dirix and Dr. Kunstfeld reported having no financial conflicts of interest.